Compare EIG & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIG | FTRE |
|---|---|---|
| Founded | 2000 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.0M | 829.3M |
| IPO Year | 2006 | 2023 |
| Metric | EIG | FTRE |
|---|---|---|
| Price | $41.20 | $9.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.39 |
| AVG Volume (30 Days) | 201.5K | ★ 1.3M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | $858,700,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.76 | $3.01 |
| P/E Ratio | $89.43 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $35.73 | $3.97 |
| 52 Week High | $49.98 | $18.67 |
| Indicator | EIG | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 43.43 |
| Support Level | $40.58 | $8.85 |
| Resistance Level | $42.57 | $11.22 |
| Average True Range (ATR) | 0.79 | 0.60 |
| MACD | 0.31 | 0.15 |
| Stochastic Oscillator | 77.81 | 60.19 |
Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations, through its wholly owned subsidiaries.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.